Assignee
IOMX THERAPEUTICS AG
DE·3 granted patents·14 pending applications·0 citations·filing 2017–2025
Top patents by PatentIndex Score
17 records- 0171US2025084076A1Heterocyclic kinase inhibitors and uses thereofIOMX THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 0271US2025101015A1Heterocyclic kinase inhibitors and uses thereofIOMX THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 0364US2025340886A1Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereofIOMX THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 0462US12139480B25-thiazolecarboxamide kinase inhibitor and uses thereofIOMX THERAPEUTICS AG·Filed 2019·Granted Nov 12, 2024·0 cites·18 claims
- 0557US2021379067A1Dasatinib and another 5-thiazolecarboxamide kinase inhibitor, and uses thereofIOMX THERAPEUTICS AG·Filed 2019·Application pending·0 cites
- 0656US2025241913A1Combination therapies based on pd-1 inhibitors and sik3 inhibitorsIOMX THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 0753US2025249000A1Sik3 inhibitors for treating diseases resistant to death receptor signallingIOMX THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 0851US12172993B2Heterocyclic kinase inhibitors and uses thereofIOMX THERAPEUTICS AG·Filed 2019·Granted Dec 24, 2024·0 cites·53 claims
- 0948US12338440B2Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereofIOMX THERAPEUTICS AG·Filed 2018·Granted Jun 24, 2025·0 cites·33 claims
- 1047US2023192701A1Bicyclic kinase inhibitors and uses thereofIOMX THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1147US2025296928A1A synthesis scheme and procedures for preparing a sik3 inhibitor and intermediates thereofIOMX THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 1245US2024010720A1Antibodies binding igv of igsf11 (vsig3) and uses thereofIOMX THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 1344US2023348453A1Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereofIOMX THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1441US2023228760A1Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereofIOMX THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1540US2022372138A1Antibodies binding igc2 of igsf11 (vsig3) and uses thereofIOMX THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 1635US2020024347A1Or10h1 antigen binding proteins and uses thereofIOMX THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 1732US2021061908A1Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereofIOMX THERAPEUTICS AG·Filed 2019·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →